RAM
IBRX icon

Readystate Asset Management’s ImmunityBio IBRX Stock Holding History

Readystate Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-124,885
Closed -$376K – 757
2025
Q1 		$376K Hold
124,885
– – 0.01% 506
2024
Q4 		$320K Hold
124,885
– – 0.01% 545
2024
Q3 		$465K Hold
124,885
– – 0.01% 483
2024
Q2 		$789K Buy
+124,885
New +$823K 0.03% 378

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Readystate Asset Management's IBRX Position: Q2 2025 in Review

Readystate Asset Management sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 124,885 shares — an estimated $376K sold.

Readystate Asset Management first reported a position in IBRX in Q2 2024 and held it in 4 quarters. The position peaked at $789K in Q2 2024. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

  • Readystate Asset Management reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
  • Readystate Asset Management sold 124,885 ImmunityBio shares in Q2 2025, an estimated $376K.
  • Readystate Asset Management first reported a position in ImmunityBio in Q2 2024 and held it in 4 quarters.
  • Readystate Asset Management's ImmunityBio position peaked at $789K in Q2 2024.
  • 241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Readystate Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.